Particle.news
Download on the App Store
3 ARTICLES
·
10h ago

Australia Probes Exposure as U.S. Imposes 100% Tariff on Branded Pharmaceuticals

Officials are reviewing if blood and plasma exports will be captured by the measure.

WASHINGTON, DC - SEPTEMBER 22: U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025 in Washington, DC. Federal health officials suggested a link between the use of acetaminophen during pregnancy as a risk for autism, although many health agencies have noted inconclusive results in the research. (Photo by Andrew Harnik/Getty Images)

Overview

  • President Donald Trump confirmed a 100% tariff on foreign-made pharmaceuticals after first threatening action in July.
  • Health Minister Mark Butler said the bulk of Australia's U.S.-bound shipments are blood and plasma products and their status under the policy remains unclear.
  • Butler pointed to possible exemptions for companies making capital investments in the United States.
  • Australia's major blood and plasma exporter is expanding its U.S. facilities and employs thousands there, which could support exemption eligibility.
  • Canberra is assessing potential impacts as some medicine exporters may still be hit, with start-up firms reliant on FDA approval facing added uncertainty.